A. Samer Al-Homsi, MD, MBA
Northwell Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name A. Samer Al-Homsi, MD, MBA as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:59 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05289167 · Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)Northwell Health · recruiting · Graft-versus-host Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 157 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- AIM-AHEAD Coordinating Center - All Four CoresOT2OD032581 · OD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · fiscal years 2022 to 2026 · $3,410,884 awarded in 2026Same name and institution; not confirmed by an ID
- The Impact of Diabetes on Patients with Glomerular Disease: CureGN-DiabetesR01DK126959 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · fiscal years 2021 to 2026 · $592,933 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.